Drug
CYC065 clinical trials
Also written CYC065 and Fadraciclib.
Keep track of what changes. Save the CYC065 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
Cyclacel Pharmaceuticals, Inc. (6) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Ribociclib (1) · Topotecan (1) · Temozolomide (1) · Everolimus (1) · Adavosertib (1) · Carboplatin (1) · Olaparib (1) · Irinotecan (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses CYC065 is read from its arms, and is right about nine times in ten.
Testing it · 7
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Fadraciclib
- A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and LymphomaRecruitingPhase 1/2Cyclacel Pharmaceuticals, Inc.NCT04983810Written as Fadraciclib
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSCompletedPhase 1Cyclacel Pharmaceuticals, Inc.NCT04017546Written as CYC065
- Absorption, Metabolism, and Excretion of CYC065 in Healthy Male SubjectsCompletedEarly Phase 1Cyclacel Pharmaceuticals, Inc.NCT05817890Written as Fadraciclib
- A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced CancersCompletedPhase 1Cyclacel Pharmaceuticals, Inc.NCT02552953Written as CYC065
- A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)SuspendedPhase 1/2Cyclacel Pharmaceuticals, Inc.NCT05168904Written as fadraciclib
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLCompletedPhase 1Cyclacel Pharmaceuticals, Inc.NCT03739554Written as CYC065
Codes
What other systems call CYC065 · ClinicalTrials.gg INT000746
- MeSH (NLM) C000621593CYC065One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621593 | CYC065 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.